Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Nicox SA

  • Michele GARUFI , Nicox

Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Our portfolio includes three programs in development all of which are in, or preparing to, enter Phase 2 clinical studies: NCX 470 for glaucoma, NCX 4251 for blepharitis and NCX 4280 for morning ocular congestion. Our pipeline also includes future generation stand alone NO donors in the research stage and other exploratory novel NO donating compounds targeting ophthalmic conditions. We have two ophthalmology assets approved by the U.S. FDA; VYZULTA exclusively licensed worldwide to Bausch + Lomb and commercialized in the U.S. since December 2017 as well as ZERVIATE exclusively licensed in the U.S. to Eyevance with a commercial launch in the U.S planned for spring 2019

  • Date:Tuesday, February 12
  • Time:11:00 AM - 11:15 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23293
  • Goal for Presentation:Into 2019, an exciting year of expected progresses for Nicox
  • Company Website:www.nicox.com
  • Company HQ City:Valbonne
  • Company HQ Country:France
  • Market Cap:€ 170 M
  • Ticker:COX
  • Exchange:Euronext
  • CEO/Top Company Official:Michele Garufi
  • Year Founded:1996
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development:NCX 470
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
Speakers
Michele GARUFI
Nicox
Back